by Blood
Study findings support the oral microbiome as a potential pathway for preventing or managing chronic graft-versus-host disease (cGVHD) following hematopoietic cell transplantation (HCT).
by ASTCT Advocacy Update
The ASTCT Committee on Payer Relations has updated its standardized Request for Information (RFI) forms for 2025.
by Rahul Banerjee, MD, FACP
One of the most predictable toxicities of autologous stem cell transplantation (ASCT) for multiple myeloma (MM) — even more so than mucositis — is hair loss.
by Rahul Banerjee, MD, FACP
For over 30 years, autologous stem cell transplantation (ASCT) has remained a key component of first-line treatment for multiple myeloma (MM).
by Alex Kadhim
Recent studies from Vall d’Hebron University Hospital, Heidelberg University Hospital, and the European Society for Blood and Marrow Transplantation (EBMT) provide valuable insights into the...
by Blood Advances
While both are accepted rescue therapies for classic Hodgkin lymphoma (cHL) relapse, research suggests immune checkpoint inhibitors (ICIs) offer an advantage over chemotherapy.